Oncology

Anaveon reveals promising ASCO data for its cancer drug ANV600, yet puts the asset on the market to fund a bold new focus on autoimmune diseases.

An innovative RNA-editing therapy for hepatocellular carcinoma has received a major FDA designation, potentially accelerating its path to patients.

Artivion posts strong Q1 results and acquires Endospan for its FDA-approved NEXUS system, yet lowers its full-year guidance. What's behind the mixed message?

The Italian pharma giant appoints a global health policy heavyweight, signaling a strategic pivot towards tackling complex global challenges and a new era.

With key clinical data on the horizon for its cancer and ALS drugs, LeonaBio adds deep financial, operational, and strategic expertise to its leadership.

Vancouver's ME Therapeutics will unveil its in-vivo immune reprogramming technology, a potential cancer treatment game-changer, to global investors.

A landmark European trial for a new genomic test has passed 50% recruitment, promising to tailor breast cancer therapy and improve patient quality of life.

With a promising cancer pipeline, Crescent Biopharma heads to key May conferences to prove its strategy against fierce competition in the bispecific and ADC markets.

Meet the three finalists for the 2026 Extraordinary Healer® Award, recognizing the oncology nurses whose compassion and skill transform patient care.

Creatv Bio will present data at ASCO 2026 on its LifeTracDx® blood test, showcasing its potential to personalize cancer treatment through key pharma partnerships.

A new all-in-one system from Sweden's Multi4 Medical just won EU approval, allowing urologists to treat bladder cancer in minutes without surgery.

With a star-studded new advisory board, Pilatus Biosciences accelerates its attack on cancer's metabolic defenses with its lead drug, PLT012.

With new strategic financing and powerhouse board appointments, 4D Path is accelerating its novel AI platform that predicts cancer treatment success from a single slide.

UK biotech Cytospire Therapeutics secures major funding to push its safer, more selective gamma delta T-cell engager into clinical trials for solid tumors.

At the elite FiRe 2026 conference, Pattern Computer plans to unveil a 'hallucination-free' AI, promising a new era of scientific discovery and trust.

A major investment in natural killer cell immunotherapy aims to revolutionize treatment for Canada's most fatal women's cancer after decades of stagnation.

A strategic investment from FreeMind Investments and Daewoong Pharma validates General Proximity's novel platform for next-gen induced proximity medicines.

The clinical-stage biotech adds seasoned veterans from Eli Lilly and Iovance to accelerate its promising DNA Damage Response pipeline toward commercialization.

Spanish CDMO ROIS acquires a major Phoenix facility from Bristol Myers Squibb, securing US drug supply chains and expanding its global footprint.

A $1M grant funds research into an ultra-rare cancer's defense mechanism, offering new hope against a disease with a grim 10% survival rate.